1. Aliskiren: Renin Inhibitor 2. Ambrisentan: Endothelin receptor antagonist for treatment of pulmonary hypertension. 3. Anidulafungin: Echinocandin antifungal for treatment of candidemia, abcess, oesophagial candidasis. 4. Armodafinil : CNS stimulant, R- enantiomer of Modafinil 5. Atomoxetine: CNS noradrenaline (NA) reuptake inhibitor, first and only FDA approved non-stimulant drug for treatment of ADHD. 6. Bosentan: Endothelin-1- Antagonist, Cardiac remodeling inhibitor. Used for Rx of PPH. 7. Candoxatrilat: Inhibit Neutral Endopeptidase, increases ANP. 8. Carperitide: Recombinant BNP. 9. Cinacalcet is an oral calcimimetic agent that increases the sensitivity of the calcium-sensing receptor to activation by extracellular calcium. The calcium-sensing receptors on the surface of parathyroid gland cells also regulate parathyroid hormone (PTH) secretion. Increasing the sensitivity of these receptors results in lowering of PTH which subsequently lowers serum calcium levels. In addition, significant reductions in calcium may lower the threshold for seizures. Sensipar is an oral calcimimetic medication that lowers the levels of parathyroid hormone, phosphurous and calcium in patients undergoing kidney dialysis or in patients with parathroid cancer. Cinacalcet (Senipar) is indicated for the treatment of secondary hyperparathyroidism in chronic kidney disease patients on dialysis and the treatment of elevated calcium levels (hypercalcemia) in patients with parathyroid carcinoma. The recommended starting oral dose of Sensipar is 30 mg once daily. 10. Conivaptan is a non-peptide dual arginine vasopressin (AVP) V1A and V2 receptor antagonist. It is designed to inhibit the effects of AVP, also known as antidiuretic hormone (ADH), is specifically indicated for the treatment of SIADH. . In the kidneys, AVP's activity (primarily at V2 receptors) inhibits aquaresis, or excretion of free water. By exerting antagonistic activity at both V1A and V2 receptors, the drug is designed to inhibit inappropriate/excessive AVP secretion, thereby increasing rates aquaresis. Increased water secretion is correlated with net fluid loss, increased urinary output, and decreased urinary osmolality. Can cause hypokalemia, edema, pollakuria(daytime excessive urination) 11. Darunavir: Protease Inhibitor. 12. Dofetilide: Potassium Channel Blocker. 13. Enoximone: PDE IIIa inhibitor (Amrinone/Milrinone) 14. Eplerenone: Aldosterone antagonist. 15. Etomoxir: pFOX (Fatty acid oxidase) inhibitor. 16. Guanfacine: a selective alpha-2A- adrenoceptor agonist of CNS for ADHD. 17. HPV Vaccine (GARDASIL) against HPV 6, 11, 16 and 18. 18. Irinotecan: Topoisomerase 1 inhibitor, called CPT-11, a Camptothecin molecule, anti- leukemia agent, also useful in Colon carcinoma, producing a metabolite SN-38 which produces secretory diarrhoea manageable with Loperamide or Octreotide, and also myelosuppression especially with patients with deficient UGT1A1. 19. Istaroxime: Na+/K+ -ATPase inhibitor (E.g. Digoxin), FIRST DRUG to target LUSITROPY. 20. Ixabepilone: Microtubule inhibitor for monotherapy for metastatic breast cancer after treatment failure with other agents. 21. Lapatinib : Kinase inhibitor used in metastatic breast cancer with HER2 overexpression. 22. Lenalidomide is an orally available thalidomide analog, exerting both anti-angiogenic and immunomodulatory/anti- inflammatory properties. Thrombocytopenia and neutropenia were the most frequently observed serious adverse events. 23. Lenalidomide: An IMID â€“ Immunomodulatory derivative of Thalidomide. 24. Levosimendan: Calcium sensitizer. 25. Maprotiline: 2nd gen. antidepressant, with predominant NA reuptake inhibitor, little anticholinergic side effects, but may produce seizures. 26. Maraviroc â€“ the first chemokine receptor antagonist, Entry Inhibitor for drug resistant HIV infection. Maraviroc blocks the main route of virus entry into uninfected cellsâ€”chemokine receptor 5 (CCR5). 27. Mecasermin contains recombinant-DNA-engineered human insulin-like growth factor-1 (rhIGF-1). It is designed to replace natural IGF-1 in pediatric patients who are deficient, promoting normalized stature growth. Patients with severe primary IGF-1 deficiency (Primary IGFD) fail to produce adequate levels of IGF-1, due to disruption of the growth hormone (GH) pathway used to promote IGF-1 release (possible GH pathway disruptions include mutations in the GH receptor (GHR), post-GHR signaling pathway, and IGF-1 gene defects) and is specifically indicated for the long-term treatment of growth failure in pediatric patients with Primary IGFD or with GH gene deletion who have developed neutralizing antibodies to GH. It is not indicated to treat Secondary IGFD resulting from GH deficiency, malnutrition, hypothyroidism or other causes; it is not a substitute for GH therapy. 28. Modafinil: for patients with narcolepsy, sleep apnea, and shift work sleep disorder. 29. Natalizumab: recombinant humanized IgG4k monoclonal antibody produced in murine myeloma cells and is indicated for the treatment of patients with relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations, 300 mg IV infusion every four weeks. 30. Nesiritide: Recombinant BNP. 31. Omapatrilat: Inhibits both ACE and Neutral Endopeptidase. 32. Pegaptanib: is a selective vascular endothelial growth factor (VEGF) antagonist, is indicated for the treatment of neovascular (wet) age-related macular degeneration. 33. Pemetrexed is a chemotherapy drug that interferes with three folic acid related enzymes (an antifolate antineoplastic agent), is indicated, in combination with Cisplatin, for the treatment of malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery. 34. Perhexiline: pFOX (Fatty acid oxidase) inhibitor. 35. Raltegravir â€“ is the first integrase inhibitor for drug resistant HIV infection. 36. Rifaximin - treatment of travelersâ€™ diarrhea caused by noninvasive strains of Escherichia coli in patients 12 years old and older. 37. Sorafenib is a multikinase inhibitor targeting a number of serine/threonine and receptor tyrosine kinases, is specifically indicated for the treatment of advanced renal cell carcinoma (RCC). 38. Tezosentan: Endothelin-1- Antagonist, Cardiac remodeling inhibitor. 39. Tipranavir is a non-peptide protease inhibitor which selectively inhibits virus-specific processing of viral Gag and Gag-pol polyproteins, preventing formation of functional mature virions. 40. Ularitide: Recombinant Urodilantin, a natriuretic peptide similar to ANP, BNP. 41. Zoledronic Acid: First one yearly therapy for Osteoporosis, for Pagetâ €™s disease and post-menopausal osteoporosis.